<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/24A1EE66-AE01-4E27-9C73-48C3A1C90C77"><gtr:id>24A1EE66-AE01-4E27-9C73-48C3A1C90C77</gtr:id><gtr:name>PATH</gtr:name><gtr:address><gtr:line1>PATH</gtr:line1><gtr:line2>2201 Westlake Avenue, Suite 200</gtr:line2><gtr:line3>PO Box 900922</gtr:line3><gtr:postCode>98109</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CC092EB8-FCC2-42C2-9E65-F6368A54E233"><gtr:id>CC092EB8-FCC2-42C2-9E65-F6368A54E233</gtr:id><gtr:name>Clinton Health Access Initiative (CHAI)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/734F19C1-61E5-45B1-A183-63FDD145328F"><gtr:id>734F19C1-61E5-45B1-A183-63FDD145328F</gtr:id><gtr:name>World Health Organization (WHO)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Infectious Disease Epidemiology</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/24A1EE66-AE01-4E27-9C73-48C3A1C90C77"><gtr:id>24A1EE66-AE01-4E27-9C73-48C3A1C90C77</gtr:id><gtr:name>PATH</gtr:name><gtr:address><gtr:line1>PATH</gtr:line1><gtr:line2>2201 Westlake Avenue, Suite 200</gtr:line2><gtr:line3>PO Box 900922</gtr:line3><gtr:postCode>98109</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CC092EB8-FCC2-42C2-9E65-F6368A54E233"><gtr:id>CC092EB8-FCC2-42C2-9E65-F6368A54E233</gtr:id><gtr:name>Clinton Health Access Initiative (CHAI)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/734F19C1-61E5-45B1-A183-63FDD145328F"><gtr:id>734F19C1-61E5-45B1-A183-63FDD145328F</gtr:id><gtr:name>World Health Organization (WHO)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/A8E6283C-60CB-44AF-A152-DBAC1C77702F"><gtr:id>A8E6283C-60CB-44AF-A152-DBAC1C77702F</gtr:id><gtr:firstName>Jamie</gtr:firstName><gtr:otherNames>Thomas</gtr:otherNames><gtr:surname>Griffin</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1002284"><gtr:id>DEF03F6D-F3F3-4BF6-AB45-C28AF3E28EE9</gtr:id><gtr:title>Synthesising data from multiple spatial scales and levels of detail to improve malaria transmission model predictions</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G1002284</gtr:grantReference><gtr:abstractText>In recent years the goal of malaria eradication has been put forward. Mathematical models of malaria transmission are valuable for understanding which control measures will be most effective, given the local conditions. I will statistically fit malaria models to a wide range of data sources. Then I will use data where the genetic make-up of the malaria parasites that people are infected with is known, in order to estimate how fast infection spreads through space on a local scale. 
Together, these results will improve our ability to choose the most appropriate control measures. This will allow us to use limited resources more effectively, and hence have a greater chance of eliminating malaria altogether from some areas, or of controlling disease at a low level. The results will also help in designing strategies which aim to optimise the use of resources by targeting interventions at local foci of infection. The statistical methods developed will also be helpful for those modelling other infectious diseases who need to make use of diverse types of data, or who would like to use genetic data to estimate quantities that affect the spread of infection.</gtr:abstractText><gtr:technicalSummary>Introduction
In recent years there has been a renewed effort to control malaria, with eradication as the ultimate goal. Mathematical models of malaria transmission are valuable tools to help us to understand which combinations of control measures will be most effective, and how to tailor control programmes to local conditions. However there has been limited work validating such models against data. Furthermore, malaria transmission is locally heterogeneous, but more needs to be known in order to effectively target local foci of infection (hotspots). 
Aims
My aims are the following:
1) choose among possible models for acquisition of immunity to malaria;
2) improve these models? predictions of the impact of control measures;
3) estimate how fast malaria spreads through space at a local level;
4) determine which methods for detecting hotspots work best;
5) predict the impact of targeting of interventions at local hotspots of transmission.
Methodology
I will have access to many datasets with differing levels of detail and spatial scales. First, I will fit transmission models to the datasets that do not have control measures, to choose the best model for how various kinds of immunity develop. Then I will fit extensions of this model to datasets recording the impact of interventions. 
I will develop and apply methods to use data of genotyped infections and their spatial location to estimate the rate at which malaria infections spread through space and time from person to person (via mosquitoes). I will then use simulation to compare methods for detecting hotspots, and combine these results to design and assess strategies which target hotspots. 
Outcomes
Together, these results will improve the predictions of malaria models, allowing us to use limited resources more effectively, thus having a greater chance of eliminating malaria altogether from some areas, or of controlling disease at a low level. The results will also aid the design of strategies which aimo optimise the use of resources by targeting interventions at hotspots of infection.
The work will also result in methodological developments in a number of areas. It will require a comprehensive statistical framework for validating infectious disease models, combining methods that are not generally applied to complex biologically-based models. I will develop novel methods for estimating quantities relevant to infection processes from partially observed genetic data; and assess and develop methods to detect clusters of infectious disease transmission.</gtr:technicalSummary><gtr:fund><gtr:end>2015-09-29</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-09-30</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>418907</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>World Health Organization (WHO)</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:department>Global Malaria Programme</gtr:department><gtr:description>Elimination scenario planning</gtr:description><gtr:id>82051749-87C0-4994-BCEC-FF072A45EB16</gtr:id><gtr:impact>A workshop was held with the national malaria control programme managers from Gambia and Senegal, in the Gambia in May 2012, organised by WHO and CHAI, and which I also attended. We discussed the WHO/CHAI malaria eliminate planning document, and had a session in which control programme managers ran my model for themselves using their own baseline data as inputs.
Following feedback from this workshop, a final version of the document is being prepared, and will be released more widely, accompanied by my malaria model.</gtr:impact><gtr:outcomeId>SQWYAsUx9LZ-1</gtr:outcomeId><gtr:partnerContribution>The WHO Global Malaria Programme and the Clinton Health Access Initiative (CHAI) have written a guide for countries planning to eliminate malaria.</gtr:partnerContribution><gtr:piContribution>I have programmed a malaria transmission model, with an easy-to-use interface. This is being used to accompany a guide for malaria elimination planning, to help malaria control programme staff to understand the possible effect of interventions against malaria.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Clinton Health Access Initiative (CHAI)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Elimination scenario planning</gtr:description><gtr:id>2E996620-A307-4D3B-B9D2-23A9701BEBBC</gtr:id><gtr:impact>A workshop was held with the national malaria control programme managers from Gambia and Senegal, in the Gambia in May 2012, organised by WHO and CHAI, and which I also attended. We discussed the WHO/CHAI malaria eliminate planning document, and had a session in which control programme managers ran my model for themselves using their own baseline data as inputs.
Following feedback from this workshop, a final version of the document is being prepared, and will be released more widely, accompanied by my malaria model.</gtr:impact><gtr:outcomeId>SQWYAsUx9LZ-2</gtr:outcomeId><gtr:partnerContribution>The WHO Global Malaria Programme and the Clinton Health Access Initiative (CHAI) have written a guide for countries planning to eliminate malaria.</gtr:partnerContribution><gtr:piContribution>I have programmed a malaria transmission model, with an easy-to-use interface. This is being used to accompany a guide for malaria elimination planning, to help malaria control programme staff to understand the possible effect of interventions against malaria.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>London School of Hygiene and Tropical Medicine (LSHTM)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Clinical Research</gtr:department><gtr:description>School-based anti-malarial prophylaxis</gtr:description><gtr:id>EB5F7A03-CD72-4FD6-A7C5-89ACD02A4784</gtr:id><gtr:impact>None</gtr:impact><gtr:outcomeId>DpTv5v6HDvG-1</gtr:outcomeId><gtr:partnerContribution>They are conducting a trial of the strategies mentioned, in Uganada.</gtr:partnerContribution><gtr:piContribution>I provided mathematical modelling results to help estimate the potential effect in reducing morbidity and transmission that could be acheived with various anti-malarial drug delivery strategies for school-children. This helped to inform sample size calculations.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Computer Science</gtr:department><gtr:description>Malaria Tools</gtr:description><gtr:id>1632AFF2-2C32-497C-9115-83552E803415</gtr:id><gtr:impact>The Malaria Tools software.</gtr:impact><gtr:outcomeId>sEV1XxYijVg-1</gtr:outcomeId><gtr:partnerContribution>Dan Stoyanov implemented a graphical interface that has been added to the malaria model.</gtr:partnerContribution><gtr:piContribution>I have programmed a malaria transmission model, described in more detail under research materials (Malaria Tools).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>World Health Organization (WHO)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Global technical strategy</gtr:description><gtr:id>C9C4FD43-9A5E-437A-9587-8101C57B9EAE</gtr:id><gtr:impact>The WHO is preparing guidance on what reduction in malaria burden is acheivable over the next ten years. The simulations I have done have helped to inform this process.</gtr:impact><gtr:outcomeId>5460cf260f4c00.37395276-1</gtr:outcomeId><gtr:partnerContribution>Staff at the WHO have provided me with data and we have discussed what are realistic assumptions for the work.</gtr:partnerContribution><gtr:piContribution>I have extended the malaria transmission model that I previously developed and the input data it depends on to provide estimates to the WHO of the likeliky global impact on malaria illness and deaths under various future scenarios.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>PATH</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:department>PATH Malaria Vaccine Initiative</gtr:department><gtr:description>Malaria Vaccine Initiatve</gtr:description><gtr:id>3573C85F-05F4-466C-B2EE-B0B1DA980C29</gtr:id><gtr:impact>MVI advises on and funds research into malaria vaccines. Our collaboration has helped to refine their advice. We provided results to GAVI, which funds vaccination on low income countries, to help with their decisions about whether to fund the new malaria vaccine (RTSS).</gtr:impact><gtr:outcomeId>hYP3iR4LdUC-1</gtr:outcomeId><gtr:partnerContribution>MVI have their own estimates of impact derived using different methods.</gtr:partnerContribution><gtr:piContribution>I have used our malaria transmission model to estimate the impact that vaccination of infants would have on morbidity, and have met with people from MVI to compare with their results and understand the differences.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Monitoring &amp;amp; Evaluation Reference Group</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>1601036A-6A72-4FA4-A2D3-9153D01FFA64</gtr:id><gtr:outcomeId>iyMbpPG9qnL</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Elimination scenario planning</gtr:description><gtr:geographicReach>Africa</gtr:geographicReach><gtr:id>3473FECF-9E42-49E1-96A3-D66577172376</gtr:id><gtr:outcomeId>Ch1YRwMCYh7</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>WHO assessment of malaria vaccine cost-effectiveness</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>FBB493F1-7B61-424B-8543-D46173A8F67C</gtr:id><gtr:outcomeId>tR2dcs45ErM</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>I have programmed a malaria transmission model, with an easy-to-use interface programmed by Dr Danail Stoyanov at UCL. The model can be freely downloaded, and users can then run it on their PC to look at the impact on malaria transmission of combinations of interventions. An Ipad version is under development. A previous version was released in 2010. In the past year, the model has been substantially improved: I have parameterised it for locations across Africa, and users can now enter their own data to specify the setting in which the simulation model runs.</gtr:description><gtr:id>EB165873-F7A0-4A98-A7AA-3C6D98C87337</gtr:id><gtr:impact>The model accompanies an Elimination Scenario Planning document produced by the WHO Global Malaria Programme and the Clinton Health Access Initiative.</gtr:impact><gtr:outcomeId>rPGNkNXA7xs</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Malaria Tools</gtr:title><gtr:type>Data analysis technique</gtr:type><gtr:url>https://www1.imperial.ac.uk/publichealth/departments/ide/research_groups/malaria/malariatools/</gtr:url></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>9053B559-7DA8-439E-A8F4-5DA34F5EC165</gtr:id><gtr:title>Serology describes a profile of declining malaria transmission in Farafenni, The Gambia.</gtr:title><gtr:parentPublicationTitle>Malaria journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a6755bcf9927bd4a9fd308ef1f5cd7e0"><gtr:id>a6755bcf9927bd4a9fd308ef1f5cd7e0</gtr:id><gtr:otherNames>van den Hoogen LL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1475-2875</gtr:issn><gtr:outcomeId>57443543da1ee6.00648983</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4C85AA3E-D359-4C19-BB16-6EBDD76ED664</gtr:id><gtr:title>Factors determining the occurrence of submicroscopic malaria infections and their relevance for control.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f24279cb762cddc202acc37d8f569f7"><gtr:id>4f24279cb762cddc202acc37d8f569f7</gtr:id><gtr:otherNames>Okell LC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>doi_13672_ncomms2241</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4D805432-65E8-4BC4-913B-0BABE325C431</gtr:id><gtr:title>Dynamics of the antibody response to Plasmodium falciparum infection in African children.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f56584c638d4ce39ec15347d619b6f1"><gtr:id>8f56584c638d4ce39ec15347d619b6f1</gtr:id><gtr:otherNames>White MT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>5460c8e4a5ac33.98140477</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8E278FBD-8872-4ACA-B3B8-A81DD13737DF</gtr:id><gtr:title>The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/61f0c0bf6603dbb3b5b9a220fc0c55e6"><gtr:id>61f0c0bf6603dbb3b5b9a220fc0c55e6</gtr:id><gtr:otherNames>Bhatt S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>5a324e37638a80.66603248</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5BE1A974-92B8-4035-80C2-1A1A31C33D1E</gtr:id><gtr:title>The impact of pyrethroid resistance on the efficacy and effectiveness of bednets for malaria control in Africa.</gtr:title><gtr:parentPublicationTitle>eLife</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/38bdeaa71df425665fb03a0331c8d987"><gtr:id>38bdeaa71df425665fb03a0331c8d987</gtr:id><gtr:otherNames>Churcher TS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2050-084X</gtr:issn><gtr:outcomeId>58c7e9962d0766.75485820</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1A4A43C-07ED-43D8-8CBB-36D12B144FA7</gtr:id><gtr:title>Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f24279cb762cddc202acc37d8f569f7"><gtr:id>4f24279cb762cddc202acc37d8f569f7</gtr:id><gtr:otherNames>Okell LC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5744349924ae32.67969362</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B458B40B-C73C-41D5-A41A-ADB31A1A3140</gtr:id><gtr:title>Is a reproduction number of one a threshold for Plasmodium falciparum malaria elimination?</gtr:title><gtr:parentPublicationTitle>Malaria journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/759ea59350160bfe2f4ff46945690745"><gtr:id>759ea59350160bfe2f4ff46945690745</gtr:id><gtr:otherNames>Griffin JT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1475-2875</gtr:issn><gtr:outcomeId>585d6a0f02e8e6.77900293</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6180E2C7-FB9F-4F9D-9980-F1558E647A14</gtr:id><gtr:title>A model of parity-dependent immunity to placental malaria.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/256159da0b605caed5f2456efb37ed15"><gtr:id>256159da0b605caed5f2456efb37ed15</gtr:id><gtr:otherNames>Walker PG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>doi_13672_ncomms2605</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DA477221-ADF4-4485-AEDA-07FFA05C840F</gtr:id><gtr:title>The design and statistical power of treatment re-infection studies of the association between pre-erythrocytic immunity and infection with Plasmodium falciparum.</gtr:title><gtr:parentPublicationTitle>Malaria journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f56584c638d4ce39ec15347d619b6f1"><gtr:id>8f56584c638d4ce39ec15347d619b6f1</gtr:id><gtr:otherNames>White MT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1475-2875</gtr:issn><gtr:outcomeId>doi_13672_875_12_278</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71C5A348-B0B9-4B08-AF2C-5ABA8F49942D</gtr:id><gtr:title>Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b5658030333b8bb972d6197230bfc9aa"><gtr:id>b5658030333b8bb972d6197230bfc9aa</gtr:id><gtr:otherNames>Penny MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>5744338683d9f9.89961904</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>86379A68-6C7D-4BC6-9C14-6DAF0B979D9B</gtr:id><gtr:title>Risk factors for UK Plasmodium falciparum cases.</gtr:title><gtr:parentPublicationTitle>Malaria journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/027454f475c9478478c151d850908532"><gtr:id>027454f475c9478478c151d850908532</gtr:id><gtr:otherNames>Pinsent A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1475-2875</gtr:issn><gtr:outcomeId>5460c8e4cb1869.96283472</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4C7316C-0113-47D7-AD91-451F73076F1B</gtr:id><gtr:title>The interaction between seasonality and pulsed interventions against malaria in their effects on the reproduction number.</gtr:title><gtr:parentPublicationTitle>PLoS computational biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/759ea59350160bfe2f4ff46945690745"><gtr:id>759ea59350160bfe2f4ff46945690745</gtr:id><gtr:otherNames>Griffin JT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1553-734X</gtr:issn><gtr:outcomeId>doi_55faa2aa210791f7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D047777-59B2-4390-96E9-AE28C6361450</gtr:id><gtr:title>Seasonality in malaria transmission: implications for case-management with long-acting artemisinin combination therapy in sub-Saharan Africa.</gtr:title><gtr:parentPublicationTitle>Malaria journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f51342f6c7c83db2e5ba87a366a48f4a"><gtr:id>f51342f6c7c83db2e5ba87a366a48f4a</gtr:id><gtr:otherNames>Cairns ME</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1475-2875</gtr:issn><gtr:outcomeId>57443476e3bd64.26933441</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>74CEBD20-65F2-4329-B1E8-BE13E6A0E227</gtr:id><gtr:title>Hitting hotspots: spatial targeting of malaria for control and elimination.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/257135c67b585b044c8c4d0cf4577d5b"><gtr:id>257135c67b585b044c8c4d0cf4577d5b</gtr:id><gtr:otherNames>Bousema T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>pm_13672_22_22303287</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E9C7394-675D-4E51-82F7-7EA680CD1C39</gtr:id><gtr:title>The impact of hotspot-targeted interventions on malaria transmission: study protocol for a cluster-randomized controlled trial.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/257135c67b585b044c8c4d0cf4577d5b"><gtr:id>257135c67b585b044c8c4d0cf4577d5b</gtr:id><gtr:otherNames>Bousema T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>doi_13672_6215_14_36</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DAB11519-CA0E-4CF8-A1A7-148D9CFF05B9</gtr:id><gtr:title>Key traveller groups of relevance to spatial malaria transmission: a survey of movement patterns in four sub-Saharan African countries.</gtr:title><gtr:parentPublicationTitle>Malaria journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c4f768e77bdb0f6ed61e52b8b25a383b"><gtr:id>c4f768e77bdb0f6ed61e52b8b25a383b</gtr:id><gtr:otherNames>Marshall JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1475-2875</gtr:issn><gtr:outcomeId>57443447b07098.96649273</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7DBB4DFC-83FA-4EFA-9A20-2DCF99F8B9E6</gtr:id><gtr:title>Modelling the cost-effectiveness of introducing the RTS,S malaria vaccine relative to scaling up other malaria interventions in sub-Saharan Africa.</gtr:title><gtr:parentPublicationTitle>BMJ global health</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/345af6961b3dbf1d96b57a132e3e61f3"><gtr:id>345af6961b3dbf1d96b57a132e3e61f3</gtr:id><gtr:otherNames>Winskill P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2059-7908</gtr:issn><gtr:outcomeId>5a8f003ccc1635.87118069</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>60424280-6A8A-410F-9193-89EF1380CCFE</gtr:id><gtr:title>Potential for reduction of burden and local elimination of malaria by reducing Plasmodium falciparum malaria transmission: a mathematical modelling study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/759ea59350160bfe2f4ff46945690745"><gtr:id>759ea59350160bfe2f4ff46945690745</gtr:id><gtr:otherNames>Griffin JT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>574433c8a4f463.36309824</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CD8CC176-387E-45E8-9998-6F71EE6568F3</gtr:id><gtr:title>Global investment targets for malaria control and elimination between 2016 and 2030.</gtr:title><gtr:parentPublicationTitle>BMJ global health</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eae55e2fc6cf4324e67303c032c3beeb"><gtr:id>eae55e2fc6cf4324e67303c032c3beeb</gtr:id><gtr:otherNames>Patouillard E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2059-7908</gtr:issn><gtr:outcomeId>5a8effb9bfc263.35167043</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>45B6B115-9D2C-49FA-BD4F-C3E89159368C</gtr:id><gtr:title>Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f56584c638d4ce39ec15347d619b6f1"><gtr:id>8f56584c638d4ce39ec15347d619b6f1</gtr:id><gtr:otherNames>White MT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>57443476b11549.10741878</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>60D16DE5-6A89-4AC7-A6D0-C12E4539FC5E</gtr:id><gtr:title>Defining the relationship between infection prevalence and clinical incidence of Plasmodium falciparum malaria.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d63bdf0497cace14661db5445993c6dd"><gtr:id>d63bdf0497cace14661db5445993c6dd</gtr:id><gtr:otherNames>Cameron E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>585d576d70f292.17250002</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0783F9FE-49C8-47D8-A259-C8AA65E3B0F4</gtr:id><gtr:title>Gradual acquisition of immunity to severe malaria with increasing exposure.</gtr:title><gtr:parentPublicationTitle>Proceedings. Biological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/759ea59350160bfe2f4ff46945690745"><gtr:id>759ea59350160bfe2f4ff46945690745</gtr:id><gtr:otherNames>Griffin JT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0962-8452</gtr:issn><gtr:outcomeId>doi_55f98598597f0108</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>68198C54-7E51-4CD3-BC18-621032A8E8ED</gtr:id><gtr:title>The relationship between RTS,S vaccine-induced antibodies, CD4? T cell responses and protection against Plasmodium falciparum infection.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f56584c638d4ce39ec15347d619b6f1"><gtr:id>8f56584c638d4ce39ec15347d619b6f1</gtr:id><gtr:otherNames>White MT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>doi_13672_ne_0061395</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FE661366-2044-4D2E-911F-D9281E68C655</gtr:id><gtr:title>A combined analysis of immunogenicity, antibody kinetics and vaccine efficacy from phase 2 trials of the RTS,S malaria vaccine.</gtr:title><gtr:parentPublicationTitle>BMC medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f56584c638d4ce39ec15347d619b6f1"><gtr:id>8f56584c638d4ce39ec15347d619b6f1</gtr:id><gtr:otherNames>White MT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1741-7015</gtr:issn><gtr:outcomeId>5460c8e4f3e754.73311995</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F078CBF4-ADC5-4E67-8D8D-3FB86AE42338</gtr:id><gtr:title>Assessing the potential impact of artemisinin and partner drug resistance in sub-Saharan Africa.</gtr:title><gtr:parentPublicationTitle>Malaria journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/730ae9ad8c71b39ddf56c92de27a5308"><gtr:id>730ae9ad8c71b39ddf56c92de27a5308</gtr:id><gtr:otherNames>Slater HC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1475-2875</gtr:issn><gtr:outcomeId>57443386ab3107.27256055</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FA4629A5-7EBA-4098-AC05-3DBA2FB0C3B2</gtr:id><gtr:title>Estimating the most efficient allocation of interventions to achieve reductions in Plasmodium falciparum malaria burden and transmission in Africa: a modelling study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Global health</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/256159da0b605caed5f2456efb37ed15"><gtr:id>256159da0b605caed5f2456efb37ed15</gtr:id><gtr:otherNames>Walker PG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2214-109X</gtr:issn><gtr:outcomeId>58c7e978334826.61104741</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D3555CB2-C19D-42C6-B7EC-67F87EF9920A</gtr:id><gtr:title>Malaria morbidity and mortality in Ebola-affected countries caused by decreased health-care capacity, and the potential effect of mitigation strategies: a modelling analysis.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/256159da0b605caed5f2456efb37ed15"><gtr:id>256159da0b605caed5f2456efb37ed15</gtr:id><gtr:otherNames>Walker PG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>5675e367509e3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF74E7EB-2E5C-4970-B849-B4279AF81B27</gtr:id><gtr:title>Estimates of the changing age-burden of Plasmodium falciparum malaria disease in sub-Saharan Africa.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/759ea59350160bfe2f4ff46945690745"><gtr:id>759ea59350160bfe2f4ff46945690745</gtr:id><gtr:otherNames>Griffin JT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>pm_540e177e177e34b2d</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1002284</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>FB395309-E202-4FE8-87B0-041A3D72D4D4</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.5  Research design and methodologies (aetiology)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>